|
1
|
Chheang S and Brown K: Lung cancer
staging: clinical and radiologic perspectives. Semin Intervent
Radiol. 30:99–113. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Folkman J, Merler E, Abernathy C, et al:
Isolation of a tumor factor responsible for angiogenesis. J Exp
Med. 133:275–288. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Folkman J and Kalluri R: Cancer without
disease. Nature. 427:7872004. View
Article : Google Scholar
|
|
4
|
Browder T, Folkman J and Pirie-Shepherd S:
The hemostatic system as a regulator of angiogenesis. J Biol Chem.
275:1521–1524. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
O’Reilly MS, Boehm T, Shing Y, et al:
Endostatin: an endogenous inhibitor of angiogenesis and tumor
growth. Cell. 88:277–285. 1997.
|
|
6
|
Blezinger P, Wang J, Gondo M, et al:
Systemic inhibition of tumor growth and tumor metastases by
intramuscular administration of the endostatin gene. Nat
Biotechnol. 17:343–348. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sauter BV, Martinet O, Zhang WJ, et al:
Adenovirus-mediated gene transfer of endostatin in vivo results in
high level of transgene expression and inhibition of tumor growth
and metastases. Proc Natl Acad Sci USA. 97:4802–4807. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shan YF, Fang YF, Wang XQ, et al:
Experimental studies on treatment of pancreatic cancer with
double-regulated duplicative adenovirus AdTPHre-hEndo carrying
human endostatin gene. Pancreatology. 13:393–400. 2013. View Article : Google Scholar
|
|
9
|
Ma X, Yao Y, Yuan D, et al: Recombinant
human endostatin endostar suppresses angiogenesis and
lymphangiogenesis of malignant pleural effusion in mice. PLoS One.
7:e534492012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jia Y, Liu M, Huang W, et al: Recombinant
human endostatin endostar inhibits tumor growth and metastasis in a
mouse xenograft model of colon cancer. Pathol Oncol Res.
18:315–323. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Szarvas T, László V, Vom Dorp F, et al:
Serum endostatin levels correlate with enhanced extracellular
matrix degradation and poor patients’ prognosis in bladder cancer.
Int J Cancer. 130:2922–2929. 2012.PubMed/NCBI
|
|
12
|
Sharma BK, Srinivasan R, Kapil S, et al:
Serum levels of angiogenic and anti-angiogenic factors: their
prognostic relevance in locally advanced hepatocellular carcinoma.
Mol Cell Biochem. 383:103–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mo HY, Luo DH, Qiu HZ, et al: Elevated
serum endostatin levels are associated with poor survival in
patients with advanced-stage nasopharyngeal carcinoma. Clin Oncol
(R Coll Radiol). 25:308–317. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Homer JJ, Greenman J and Stafford ND:
Circulating angiogenic cytokines as tumour markers and prognostic
factors in head and neck squamous cell carcinoma. Clin Otolaryngol
Allied Sci. 27:32–37. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Landt S, Mordelt K, Schwidde I, et al:
Prognostic significance of the angiogenic factors angiogenin,
endoglin and endostatin in cervical cancer. Anticancer Res.
31:2651–2655. 2011.PubMed/NCBI
|
|
16
|
Feldman AL and Libutti SK: Progress in
antiangiogenic gene therapy of cancer. Cancer. 89:1181–1194. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Felbor U, Dreier L, Bryant RA, et al:
Secreted cathepsin L generates endostatin from collagen XVIII. EMBO
J. 19:1187–1194. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wen W, Moses MA, Wiederschain D, et al:
The generation of endostatin is mediated by elastase. Cancer Res.
59:6052–6056. 1999.PubMed/NCBI
|
|
19
|
Wang J, Li K, Sun T, et al: Efficacy and
safety of rh-endostatin combined with docetaxel in second-line or
intolerant toxicity for first-line treatment in patients with
advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi.
35:618–622. 2013.(In Chinese).
|
|
20
|
Xue SL, Deng X, Liu Y, et al:
Intraperitoneal recombinant human endostatin combined with
chemotherapy for refractory malignant ascites due to
gastrointestinal cancer: a pilot study. Hepatogastroenterology.
60:118–123. 2013.
|
|
21
|
Ling Y, Yang Y, Lu N, et al: Endostar, a
novel recombinant human endostatin, exerts antiangiogenic effect
via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of
endothelial cells. Biochem Biophys Res Commun. 361:79–84. 2007.
View Article : Google Scholar
|
|
22
|
Dong X, Zhao X, Xiao T, et al: Endostar, a
recombined humanized endostatin, inhibits lymphangiogenesis and
lymphatic metastasis of Lewis lung carcinoma xenograft in mice.
Thorac Cardiovasc Surg. 59:133–136. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brideau G, Mäkinen MJ, Elamaa H, et al:
Endostatin overexpression inhibits lymphangiogenesis and lymph node
metastasis in mice. Cancer Res. 67:11528–11535. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ni Q, Ji H, Zhao Z, et al: Endostar, a
modified endostatin inhibits non small cell lung cancer cell in
vitro invasion through osteopontin-related mechanism. Eur J
Pharmacol. 614:1–6. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thielemann A, Baszczuk A, Kopczyński Z, et
al: Clinical usefulness of assessing VEGF and soluble receptors
sVEGFR-1 and sVEGFR-2 in women with breast cancer. Ann Agric
Environ Med. 20:293–297. 2013.PubMed/NCBI
|
|
26
|
Matsumoto K, Suzuki K, Koike H, et al:
Prognostic significance of plasma placental growth factor levels in
renal cell cancer: an association with clinical characteristics and
vascular endothelial growth factor levels. Anticancer Res.
23:4953–4958. 2003.
|
|
27
|
Yamagata M, Shiratori Y, Dan Y, et al:
Serum endostatin levels in patients with hepatocellular carcinoma.
Ann Oncol. 11:761–762. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
George DJ, Halabi S, Shepard TF, et al:
Prognostic significance of plasma vascular endothelial growth
factor levels in patients with hormone-refractory prostate cancer
treated on Cancer and Leukemia Group B 9480. Clin Cancer Res.
7:1932–1936. 2001.
|
|
29
|
Park JH, Choi H, Kim YB, et al: Serum
angiopoietin-1 as a prognostic marker in resected early stage lung
cancer. Lung Cancer. 66:359–364. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun J, Ding I, Fenton B, et al:
Immunohistochemical identification and localization of endogenous
endostatin and its related peptides in murine tumors. Adv Exp Med
Biol. 599:147–153. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Saarela J, Rehn M, Oikarinen A, et al: The
short and long forms of type XVIII collagen show clear tissue
specificities in their expression and location in basement membrane
zones in humans. Am J Pathol. 153:611–626. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guenther U, Herbst H, Bauer M, et al:
Collagen type XVIII/endostatin is differentially expressed in
primary and metastatic colorectal cancers and ovarian carcinomas.
Br J Cancer. 85:1540–1545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chang H, Iizasa T, Shibuya K, et al:
Increased expression of collagen XVIII and its prognostic value in
nonsmall cell lung carcinoma. Cancer. 100:1665–1672. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Iizasa T, Chang H, Suzuki M, et al:
Overexpression of collagen XVIII is associated with poor outcome
and elevated levels of circulating serum endostatin in non-small
cell lung cancer. Clin Cancer Res. 10:5361–5366. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nikitakis NG, Rivera H, Lopes MA, et al:
Immunohistochemical expression of angiogenesis-related markers in
oral squamous cell carcinomas with multiple metastatic lymph nodes.
Am J Clin Pathol. 119:574–586. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Musso O, Rehn M, Théret N, et al: Tumor
progression is associated with a significant decrease in the
expression of the endostatin precursor collagen XVIII in human
hepatocellular carcinomas. Cancer Res. 61:45–49. 2001.
|
|
37
|
Yoo J, Jung JH, Lee MA, et al:
Immunohistochemical analysis of non-small cell lung cancer:
correlation with clinical parameters and prognosis. J Korean Med
Sci. 22:318–325. 2007. View Article : Google Scholar : PubMed/NCBI
|
